Time to read
1 minute
Read so far

Long-term outcomes show benefits of FiLaC anal fistula therapy

Wed, 11/29/2017 - 09:28
Posted in:

FiLaC results in a 64.1% primary cure rate and a secondary cure rate of 85.5%

A long-term study on the treatment of anal fistulas conducted on 117 patients with an average follow-up period of 25.4 months (overall study duration of 6–60 months) confirms a primary success rate of 64.1% from initial therapy using FiLaC. The secondary cure rate (a second smaller procedure) was as high as 85.5%.

In the FiLaC therapy from the medical technology firm biolitec, a flexible, radially emitting FiLaC fibre is placed precisely at the internal orifice using a pilot beam, and the energy is emitted over the course of the fistular track. The efficient irradiation concept of the FiLac fiber optimally uses the applied energy to close the fistular track. The treatment was performed using either a Ceralas or a Leonardo Dual 45 diode laser from the biolitec. This type of laser delivers energy with a wavelength of 1470nm and an optimal absorption curve in water, which has the result of efficient local tissue shrinkage and protein denaturation. All areas of the surrounding musculature remain maximally preserved. Incontinence is generally avoided. Laser therapy can also be used for coccygeal fistulas.

The study was conducted between October 2009 and July 2014 at the Cologne Rectal and Pelvic Floor Center (EBZ), Germany, on a treatment group of 117 patients with an anal fistula who were treated with the FiLaC method. The objective of the study was the observation and evaluation of the treatment method of laser ablation over a long-term period. The FiLaC procedure combines the objectives of successful fistula treatment, that is, clinical efficacy plus preservation of continence function.

A selection of the findings from the study report that:

  • No cases of incontinence of liquid stool occurred
  • The primary cure rate was 75/117 overall (64.1%); for cryptoglandular anal fistulas, it was 63.5%, and for fistulas secondary to Crohn’s disease, it was 69.2%
  • Of the 42 patients in whom FiLaC did not work, 31 underwent a further operation (fistulectomy with sphincter muscle reconstruction or fistulectomy)
  • The secondary cure rate (healing of the fistula at the end of the study period) was 103/117 overall (85.5%); for cryptoglandular anal fistulas it was 85.5%, and for fistulas secondary to Crohn’s disease, it was 92.3%
  • A significantly higher primary success rate was demonstrated for intersphincteric fistulas, with primary and secondary success— independent of age, sex, Crohn’s disease, number of previous operations, or the type of coverage using a skin flap.

The study, ‘Five years of experience with the FiLaCTM laser for fistula-in-ano management: long-term follow-up from a single institution’, was published in Techniques in Coloproctology.